Triptolide inhibits epithelial-mesenchymal transition and induces apoptosis in gefitinib-resistant lung cancer cells

The epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), gefitinib, is used widely to treat non-small cell lung cancer (NSCLC) with EGFR-activating mutations. Unfortunately, the acquired drug resistance promoted by epithelial-mesenchymal transition (EMT) markedly limits the clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fangqiong, Cui, Huaizhong, Jin, Xin, Gong, Xiaoting, Wang, Wei, Wang, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7107945/
https://www.ncbi.nlm.nih.gov/pubmed/32323848
http://dx.doi.org/10.3892/or.2020.7542

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7107945/
https://www.ncbi.nlm.nih.gov/pubmed/32323848
http://dx.doi.org/10.3892/or.2020.7542

Ejemplares similares